Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail


December 31, 2012
72 Pages - SKU: XGBR4938633
License type:
Table of Contents Search inside this report Related Reports


Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail

Summary

Leading business intelligence provider, GBI Research, has released its latest research report, entitled: “Liver Cancer Therapeutics Market to 2018 - Nexavar, the Only Approved Targeted Therapy for Advanced Disease, Continues to Dominate as Other Late Stage Trials Fail”. The report provides insights into the liver cancer therapeutics market in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan, with market forecasts until 2018. It provides in-depth analysis of the major marketed products, as well as insights into the liver cancer therapeutics R&D pipeline. The report also gives in-depth analysis of the unmet needs, drivers and barriers that affect the markets in these countries. Additionally, it discusses the global pipeline for all the liver cancer molecules across various stages of development.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research found that the liver cancer therapeutics in the top seven markets (the US, the UK, Germany, France, Spain, Italy and Japan) was estimated at $374.3m in 2011, having grown at a Compound Annual Growth Rate (CAGR) of 21.7% from 2004. Growth was driven by an increase in the patient volume and the Annual Cost of Therapy (ACT) per patient, which increased due to the approval of Nexavar (sorafenib) in the US and Europe. The market is forecast to reach revenues of $644.3m by 2018, growing at a CAGR of 8.1% from 2011.

The current competition in the liver cancer market is weak, as Nexavar is the only drug approved for advanced Hepatocellular Carcinoma (HCC) with the exception of Miripla (miriplatin) in Japan. However, there are some molecules in Phase III development as first-line and second-line treatments which promise to influence the competitive landscape in the next two to three years. The anticipated launch of Eli Lilly's ramucirumab (IMC-1121B), a monoclonal antibody in 2014; Celsion Corporation's ThermoDox in 2014; and PrevOnco in 2015 will drive the market forward.

Scope
  • Annualized market data for the liver cancer therapeutics market from 2004 to 2011 and forecast to 2018
  • Analysis of the liver cancer therapeutics market in the leading geographies of the world: the US, the UK, Germany, France, Italy, Spain, and Japan
  • Market characterization of the liver cancer therapeutics market including market size, annual cost of therapy and treatment usage patterns
  • Key drivers and barriers that affect the market
  • Coverage of pipeline molecules in various Phases of drug development
  • Competitive benchmarking of leading companies including Bayer and Dainippon Sumitomo Pharma
  • Key M&A activities and licensing agreements that have taken place between 2008 and October 2012 in liver cancer therapeutics in the top seven markets
Reasons to buy
  • Align your product portfolio to the markets with high growth potential
  • Develop market-entry and market-expansion strategies by identifying the regions and market segments poised for strong growth
  • Create a more tailored country strategy through the understanding of key drivers and barriers of the liver cancer therapeutics market
  • Develop key strategic initiatives by understanding the key focus areas and top-selling products of leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Liver Cancer Therapeutics Market to 2018 - Introduction
3 Liver Cancer Therapeutics Market to 2018 - Overview
3.1 Introduction
3.1.1 Benign Tumor
3.1.2 Primary Liver Cancer
3.1.3 Secondary Liver Cancer
3.2 Symptoms
3.3 Diagnosis
3.3.1 Laboratory Tests
3.3.2 Imaging Tests
3.3.3 Others
3.4 Treatment Options
3.4.1 Surgery
3.4.2 Non-surgical
3.4.3 General Treatment Algorithm
3.4.4 Treatment by Stage
3.4.5 New Technologies in Treatment
4 Liver Cancer Therapeutics Market to 2018 - Market Characterization and Forecasts
4.1 Revenue
4.2 Annual Cost of Therapy
4.3 Marketed Products
4.3.1 Nexavar
4.3.2 Miripla
4.4 Treatment Usage Pattern
4.4.1 Prevalence Population
4.4.2 Diagnosed Population
4.4.3 Prescription Population
4.5 Drivers and Barriers of Liver Cancer Therapeutics Market
4.5.1 Drivers
4.5.2 Barriers
5 Liver Cancer Therapeutics Market to 2018 - Geographical Landscape
5.1 US
5.1.1 Introduction
5.1.2 Revenue
5.1.3 Cost of Therapy
5.1.4 Treatment Usage Pattern
5.2 Top Five European Countries
5.2.1 Introduction
5.2.2 Revenue
5.2.3 Cost of Therapy
5.2.4 Treatment Usage Pattern
5.3 Japan
5.3.1 Introduction
5.3.2 Revenue
5.3.3 Cost of Therapy
5.3.4 Treatment Usage Pattern
6 Liver Cancer Therapeutics Market to 2018 - Pipeline Analysis
6.1 Introduction
6.2 R&D Product Pipeline by Stage of Development
6.2.1 Phase III
6.2.2 Phase II/III
6.2.3 Phase II
6.2.4 Phase I/II
6.2.5 Phase I
6.2.6 Pre-Clinical
6.2.7 Discovery
6.3 Profiles of Promising Molecules
6.3.1 PrevOnco
6.3.2 Ramucirumab
6.3.3 ThermoDox
6.3.4 Afinitor
7 Liver Cancer Therapeutics Market to 2018 - Competitive Landscape
7.1 Bayer
7.2 Dainippon Sumitomo Pharma
8 Liver Cancer Therapeutics Market to 2018 - Strategic Consolidations
8.1 Introduction
8.2 Deals by Geography
8.3 Deals by Year
8.4 Mergers and Acquisition Deals
8.4.1 Overview
8.4.2 Profiles of Major M&A Deals
8.5 Licensing Agreements
8.5.1 Overview
8.5.2 Profiles of Major Licensing Agreements
8.6 Co-Development Agreements
8.6.1 Overview
8.6.2 Profiles of Major Co-Development Agreements
9 Liver Cancer Therapeutics Market to 2018 - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Bibliography
9.4 Research Methodology
9.4.1 Coverage
9.4.2 Secondary Research
9.4.3 Primary Research
9.5 Therapeutic Landscape
9.5.2 Market Size by Geography
9.6 Geographical Landscape
9.7 Pipeline Analysis
9.8 Competitive Landscape
9.8.1 Expert Panel Validation
9.9 Contact Us
9.10 Disclaimer
1.1 List of Tables
Table 1: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue ($m), 2004-2011
Table 2: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2011-2018
Table 3: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue by Geography ($m), 2004-2011
Table 4: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2011-2018
Table 5: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2011
Table 6: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2011-2018
Table 7: Liver Cancer Therapeutics Market to 2018, Nexavar, Clinical Trial Results
Table 8: Liver Cancer Therapeutics Market, Nexavar, Adverse Reactions Reported in Clinical Trial
Table 9: Liver Cancer Therapeutics Market, Nexavar, Approval History
Table 10: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2004-2011
Table 11: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2011-2018
Table 12: Liver Cancer Therapeutics Market, US, Revenue ($m), 2004-2011
Table 13: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2011-2018
Table 14: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2011
Table 15: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2011-2018
Table 16: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2004-2011
Table 17: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2011-2018
Table 18: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue ($m), 2004-2011
Table 19: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2011-2018
Table 20: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2004-2011
Table 21: Liver Cancer Therapeutics Market to 2018, Top Five European Countries, Annual Cost of Therapy ($), 2011-2018
Table 22: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2004-2011
Table 23: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2011-2018
Table 24: Liver Cancer Therapeutics Market, Japan, Revenue ($m), 2004-2011
Table 25: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2011-2018
Table 26: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2011
Table 27: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2018
Table 28: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2004-2011
Table 29: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2011-2018
Table 30: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012
Table 31: Liver Cancer Therapeutics Market, Global, Phase III Pipeline
Table 32: Liver Cancer Therapeutics Market, Global, Phase II/III Pipeline
Table 33: Liver Cancer Therapeutics Market, Global, Phase II Pipeline
Table 34: Liver Cancer Therapeutics Market, Global, Phase I/II Pipeline
Table 35: Liver Cancer Therapeutics Market, Global, Phase I Pipeline
Table 36: Liver Cancer Therapeutics Market, Global, Preclinical, 2012
Table 37: Liver Cancer Therapeutics Market, Global, Discovery, 2012
Table 38: Liver Cancer Therapeutics Market, Global, Bayer AG, Pharmaceutical Brands, 2012
Table 39: Liver Cancer Therapeutics Market, Global, Dainippon Sumitomo Pharma, Pharmaceutical Brands, 2012
Table 40: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012
Table 41: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012
Table 42: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012
Table 43: Liver Cancer Therapeutics Market, Global, Major M&A Deals, 2007-2012
Table 44: Liver Cancer Therapeutics Market, Global, Major Licensing Agreement Deals, 2007-2012
Table 45: Liver Cancer Therapeutics Market, Global, Major Co-Development Deals, 2007-2012
1.2 List of Figures
Figure 1: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Treatment Options, 2012
Figure 2: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, General Treatment Algorithm
Figure 3: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Stage I and II, Treatment Algorithm
Figure 4: Liver Cancer Therapeutics Market, Global, Hepatocellular Carcinoma, Stage III and IV, Treatment Algorithm
Figure 5: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts ($m), 2004-2018
Figure 6: Liver Cancer Therapeutics Market, Top Seven Markets, Revenue Forecasts by Geography ($m), 2004-2018
Figure 7: Liver Cancer Therapeutics Market, Top Seven Markets, Annual Cost of Therapy ($), 2004-2018
Figure 8: Liver Cancer Therapeutics Market, Top Seven Markets, Treatment Usage Pattern (‘000), 2004-2018
Figure 9: Liver Cancer Therapeutics Market, Top Seven Markets, Drivers and Barriers, 2012
Figure 10: Liver Cancer Therapeutics Market, US, Revenue Forecasts ($m), 2004-2018
Figure 11: Liver Cancer Therapeutics Market, US, Annual Cost of Therapy ($), 2004-2018
Figure 12: Liver Cancer Therapeutics Market, US, Treatment Usage Pattern (‘000), 2004-2018
Figure 13: Liver Cancer Therapeutics Market, Top Five European Countries, Revenue Forecast ($m), 2004-2018
Figure 14: Liver Cancer Therapeutics Market, Top Five European Countries, Market Revenue ($m), 2004-2018
Figure 15: Liver Cancer Therapeutics Market, Top Five European Countries, Annual Cost of Therapy ($), 2004-2018
Figure 16: Liver Cancer Therapeutics Market, Top Five European Countries, Treatment Usage Pattern (‘000), 2004-2018
Figure 17: Liver Cancer Therapeutics Market, Japan, Revenue Forecast ($m), 2004-2018
Figure 18: Liver Cancer Therapeutics Market, Japan, Annual Cost of Therapy ($), 2004-2018
Figure 19: Liver Cancer Therapeutics Market, Japan, Treatment Usage Pattern (‘000), 2004-2018
Figure 20: Liver Cancer Therapeutics Market, Global, Pipeline Products, by Stage of Development, 2012
Figure 21: Liver Cancer Therapeutics Market, Global, Deals by Type of Agreement, 2007-2012
Figure 22: Liver Cancer Therapeutics Market, Global, Deals by Geography, 2007-2012
Figure 23: Liver Cancer Therapeutics Market, Global, Deals by Year, 2007-2012
Figure 24: GBI Research Market Forecasting Model

More Oncology/Hematology reports by GBI Research

Parenteral Nutrition Market to 2018 - Rising Incidence of Chronic Diseases such as Cancer, AIDS and Gastrointestinal (GI) Disorders, and Increased Use of Specialty Drugs Drive Growth by GBI Research
Parenteral Nutrition Market to 2018 - Rising Incidence of Chronic Diseases such as Cancer, AIDS and Gastrointestinal (GI) Disorders, and Increased Use of Specialty Drugs ...
Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise by GBI Research
Multi-Targeted Therapies - New Wave of Combination Therapies in Late Stage Development for Lung Cancer Offer Promise Summary GBI Research, the leading business intelligence provider, has released ...
Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline by GBI Research
Novel Therapies in Oncology - Protein Kinase Inhibitors, Monoclonal Antibodies and Vaccines Therapeutic Classes Dominate Late-Stage Pipeline Summary GBI Research, the leading business intelligence provider, has released ...
Pharmaceutical Pricing and Reimbursement in Oncology - Payer Pressure to Justify Premium Pricing of Novel Agents, Pushing Companies to Risk-Sharing Modalities by GBI Research
Pharmaceutical Pricing and Reimbursement in Oncology - Payer Pressure to Justify Premium Pricing of Novel Agents, Pushing Companies to Risk-Sharing Modalities Summary GBI Research, leading business intelligence ...
See all reports like this >>

 

Research assistance

We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 

Related Markets


Oncology/Hematology Reports

 
 

Share this report


Other tasks

 
 

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!